HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN) HaemaLogiX will leverage Lonza's regulatory expertise, global manufacturing footprint, and extensive experience in manufacturing monoclonal antibodies BASEL, Switzerland and SYDNEY, Jan. 28, 2022 /PRNewswire/ -- HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel...

Related Keywords

Guangzhou ,Guangdong ,China ,Sweden ,Australia ,Stockholm ,Sydney ,New South Wales ,Switzerland ,Singapore ,Swiss ,Martina Ribar Hestericov ,Dirk Oehlers ,Jeetendra Vaghjiani ,Jane Lowe ,Bryce Carmine ,Head Of External Communications ,Lonza Group Ltd ,European Hematology Association ,Swiss Exchange ,Haemalogix Ltd Contact Details ,Ir Department ,Haemalogix Ltd ,Singapore Exchange Securities Trading Limited ,Clinical Development Strategic Marketing ,Prnewswire Haemalogix Ltd Haemalogi ,Logix Ltd ,Executive Director ,Clinical Development ,Strategic Marketing ,Swiss Alps ,Scientific Advisory Board ,Multiple Myeloma ,Group Ltd ,Sequential Cohort Study Comparing Kappamab Alone ,Low Dose Dexamethasone ,